Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.
Indian J Cancer
; 52(3): 305-7, 2015.
Article
em En
| MEDLINE
| ID: mdl-26905120
ABSTRACT
BACKGROUND:
Chronic myeloid leukemia (CML), is the first malignancy that related to the chromosomal abnormality and include 15-20% of all adulthood leukemia.AIMS:
This study aimed to compare the hematologic, breakpoint cluster region-abelson (BCR-ABL) and liver function enzymes changes during treatment period of Imatinib. SETTINGS ANDDESIGN:
A noncurrent clinical trial study. MATERIALS ANDMETHODS:
New incident CML patients received Iranian made or Indian-made Imatinib after baseline measurement. Hematologic, BCR-ABL, electrolytes and liver function enzymes measured again after 24 weeks. STATISTICAL ANALYSIS USED Paired t-test and independent t-test was used to assess the effect of treatment in within and between groups, respectively.RESULTS:
Imatinib has a decreasing impact on white blood cells and placates. While an increasing effect on hemoglobin concentration. Iranian made and Indian-made Imatinib has a same effect on improvement of hematologic, BCR-ABL, electrolytes in CML patients. However, the liver changes of Imatinib were not clinically significant.CONCLUSION:
The Iranian-made Imatinib can be used as a replacement for Indian made ones without any statistical and clinical significant difference on Improvement of CML patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Mesilato de Imatinib
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article